Table 3. The validated target genes of miR-494 in the eligible studies in this meta-analysis.
| Study | Year | Type of cancer | Validated target genes |
|---|---|---|---|
| Chen [14] | 2016 | Acute Myeloid Leukemia | c-Myc |
| Li [23] | 2015 | Chondrosarcoma | SOX9 |
| Sun [24] | 2014 | Colorectal cancer | PTEN |
| Wang [27] | 2015 | Non-small cell lung cancer | PTEN |
| Li [34] | 2015 | Epithelial ovarian carcinoma | IGF1R |
| Han [21] | 2016 | Ovarian cancer | CUL4A |
| Chang [15] | 2015 | Head and neck squamous cell carcinomas | Bmi 1, ADAM10 |
| Liu [20] | 2015 | Pancreatic cancer | c-Myc, SIRT1 |
| Li [19] | 2014 | Pancreatic cancer | FOXM 1 |
| He [17] | 2014 | Gastric carcinoma | c-Myc |
Abbreviations: SOX9, SRY-related high mobility group-Box gene 9; PTEN, phosphatase and tensin homolog deleted on chromosome ten; IGF1R, insulin-like growth factor 1 receptor; CUL4A, Cullin 4A; Bmi 1, B-cell-specific moloney leukemia virus insert site 1; ADAM10, A disintegrin and metalloproteinase 10; SIRT1, Sirtuin Type 1; Foxm1, Forkhead box protein M1.